A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2–69.0%) response rate with symptom improvement in responding patients. Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowak, A K, Byrne, M J, Williamson, R, Ryan, G, Segal, A, Fielding, D, Mitchell, P, Musk, A W, Robinson, B W S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376155/
https://www.ncbi.nlm.nih.gov/pubmed/12189542
http://dx.doi.org/10.1038/sj.bjc.6600505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376155/
https://www.ncbi.nlm.nih.gov/pubmed/12189542
http://dx.doi.org/10.1038/sj.bjc.6600505

Ejemplares similares